Survival of patients with head and neck cancer. Impact of physical status and comorbidities
- PMID: 22189439
- DOI: 10.1007/s00066-011-0009-8
Survival of patients with head and neck cancer. Impact of physical status and comorbidities
Abstract
Background: Prognostic factors (e.g., gender, tumor stage, and hypoxia) have an impact on survival in patients with head and neck cancer. Thus, the impact of physical status and comorbidities on treatment decision and survival were evaluated.
Patients and methods: A total of 169 primary, inoperable patients with squamous cell cancer of the head and neck were retrospectively investigated. Patients were treated with hyperfractionated accelerated radio(chemo)therapy (HARcT) or hypofractionated radio(chemo)therapy (HypoRcT). Depending on the individual patient's situation (Karnofsky Performance Index, KPI), treatment for patients with a KPI of 80-100% was generally radiochemotherapy and for patients with a KPI ≤ 70% treatment was radiotherapy alone. In addition, all comorbidities were evaluated. Uni- and multivariate proportional hazards model were used, and overall survival (OS) was estimated by the Kaplan-Meier method.
Results: Treatment consisted of HARcT for 76 patients (45%), HART for 28 patients (17%), HypoRcT for 14 patients(8%), and HypoRT for 51 patients (30%). Of the patients, 107 patients (63%) presented with a KPI of 80-100%. OS (20%) was significantly better for patients with a KPI of 80-100%, while the OS for patients with a KPI ≤ 70% was 8% (p < 0.001). Good KPI, total irradiation dose (> 70 Gy), and chemotherapy were significant prognostic factors for better OS.
Conclusion: Our retrospective analysis shows that performance status with dependency on comorbidities was an independent risk factor for OS.
Similar articles
-
Hyperfractionated accelerated radiation therapy plus cetuximab plus cisplatin chemotherapy in locally advanced inoperable squamous cell carcinoma of the head and neck : Final 5‑year results of a phase II study.Strahlenther Onkol. 2017 Sep;193(9):733-741. doi: 10.1007/s00066-017-1145-6. Epub 2017 May 12. Strahlenther Onkol. 2017. PMID: 28500491 Clinical Trial. English.
-
Addition of chemotherapy to hyperfractionated radiotherapy in advanced head and neck cancer-a meta-analysis.Strahlenther Onkol. 2019 Dec;195(12):1041-1049. doi: 10.1007/s00066-019-01511-z. Epub 2019 Oct 4. Strahlenther Onkol. 2019. PMID: 31586229 Review. English.
-
Prognostic factors (including HPV status) for irradiation of locally advanced squamous cell carcinoma of the head and neck (SCCHN).Strahlenther Onkol. 2011 Oct;187(10):626-32. doi: 10.1007/s00066-011-1139-8. Epub 2011 Sep 19. Strahlenther Onkol. 2011. PMID: 21932027
-
Aggressive concurrent chemoradiotherapy for squamous cell head and neck cancer: an 8-year single-institution experience.Arch Otolaryngol Head Neck Surg. 1999 Feb;125(2):142-8. doi: 10.1001/archotol.125.2.142. Arch Otolaryngol Head Neck Surg. 1999. PMID: 10037279
-
[Current status of head and neck cancer therapy in the elderly].Laryngorhinootologie. 2007 Feb;86(2):95-100. doi: 10.1055/s-2006-945167. Epub 2007 Jan 11. Laryngorhinootologie. 2007. PMID: 17219330 Review. German.
Cited by
-
Primary radiotherapy or postoperative radiotherapy in patients with head and neck cancer: Comparative analysis of inflammation-based prognostic scoring systems.Strahlenther Onkol. 2015 Jun;191(6):486-94. doi: 10.1007/s00066-014-0803-1. Epub 2015 Jan 13. Strahlenther Onkol. 2015. PMID: 25583136
-
Split-course accelerated hyperfractionated irradiation (CHA-CHA) as a sole treatment for advanced head and neck cancer patients-final results of a randomized clinical trial.Br J Radiol. 2014 Sep;87(1041):20140212. doi: 10.1259/bjr.20140212. Epub 2014 Jul 16. Br J Radiol. 2014. PMID: 25027170 Free PMC article. Clinical Trial.
-
Taxane-containing induction chemotherapy followed by definitive chemoradiotherapy. Outcome in patients with locally advanced head and neck cancer.Strahlenther Onkol. 2013 Aug;189(8):618-24. doi: 10.1007/s00066-013-0397-z. Epub 2013 Jul 4. Strahlenther Onkol. 2013. PMID: 23821138 Clinical Trial.
-
Association between comorbidity and survival in head and neck cancer: Results from Head and Neck 5000.Head Neck. 2019 Apr;41(4):1053-1062. doi: 10.1002/hed.25543. Epub 2018 Dec 14. Head Neck. 2019. PMID: 30549147 Free PMC article.
-
EORTC QLQ-C15-PAL quality of life score as a prognostic indicator of survival in patients with far advanced cancer.Support Care Cancer. 2014 Jul;22(7):1941-8. doi: 10.1007/s00520-014-2173-8. Epub 2014 Mar 1. Support Care Cancer. 2014. PMID: 24577883
References
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources